TECH DATA SHEET

REPORTER VIRUS PARTICLES

DESCRIPTION	
Product	RVP-768L, SARS-CoV-2 Reporter Virus Particles (RVPs)
Lot	CL-297A
Strain	Omicron BA.1
Reporter	*Renilla* luciferase
Size	1.0 mL/vial
Packaging	20% FBS/DMEM
Recommended Input	10ul per well (96-well plate) for a S:B ≥ 200*****
Mycoplasma Test	Negative
Expiration Date	October 2025

SAFETY & HANDLING	
Shipping	Shipped on dry ice
Stability and Storage	Store at ≤ -80°C

***** Determined in the 293T-ACE2 stable cell line

SARS-CoV-2 RVPs are used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV-2 spike protein. RVPs display antigenically correct spike protein pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core. RVPs are capable of a single round of infection and carry a genome that expresses either a GFP or luciferase optical reporter gene upon infection. RVPs are produced in HEK-293T cells using three separate plasmids, encoding the spike protein, a lentiviral gag polyprotein, and a reporter gene. RVPs are created using a second-generation lentiviral system with components that are highly unlikely to recombine to produce a fully infectious virus (requiring 3 separate recombination events to do so). However, lentiviruses are capable of genomic integration and RVPs are derived from biological materials so should be handled with caution within a BSL2 or enhanced BSL2 laboratory environment. RVPs are not to be used in humans or in animals raised for food.

Thaw tubes in a 37°C water bath for 3 minutes and place on ice until ready to use. RVPs will appear as a translucent, pink solution. Gently mix prior to use and pulse tube for 3 seconds at high speed in a tabletop microfuge to recover all volume from the tube. Excessive vortexing of RVPs should be avoided. Re-freezing of RVPs is not recommended.

Integral Molecular | 3711 Market St., Suite 900, Philadelphia, PA 19104

215.966.6061
info@integralmolecular.com
www.integralmolecular.com

© Integral Molecular 2021

Updated 09/20/2022

INFECTIVITY AND NEUTRALIZATION DATA





Infectivity determined in HEK-293T cells stably over-expressing ACE2 (Integral Cat# C-HA102).

Neutralization utilized 5 µl of SARS-CoV-2 RVPs in a 384-well plate, with Integral Molecular's anti-SARS-CoV-2 monoclonal antibodies (Cat#'s IM-COV2-F06 and IM-COV2-G06). *Renilla* luciferase activity measured using the Promega *Renilla*-Glo luciferase assay system (Promega #E2710). Sample luminescence was read using a Perkin-Elmer Envision plate reader.

SIGNAL TO BACKGROUND	
RVP 384-well Input (µl)	**Signal:Background**
20	3604
10	2109
5	1004
2.5	354
1.25	189
0.625	109
0.3125	53

Signal to background is calculated using mock infected cells as the negative control value. Data are based on replicates of four wells. Devices used to read luminescence will vary in relative light unit values based on their individual detectors and software, but the signal to background will be comparable across devices.